Loading…
← CockpitCompetitor Analysis › 3148.T Create SD Holdings Co., Ltd.Open in the cockpit ↗

Create SD Holdings Co., Ltd.3148.TCompetitor analysis, valuation and peers

Japan · JPY·Consumer Staples›Drugstore Chains

Regional Japanese drugstore chain based in Shizuoka, selling OTC drugs, cosmetics and daily goods.

Momentum strong 64
Mkt cap
$1.32B
US dollars, full cap
Free float
39%
of shares outstanding
$/day
$2.14M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+8.3 pp
WACC 5.0%
Hurdle
-19 pp
Req g minus delivered
Next earnings
55 days
12 Jan 2027
Close · JPY¥3,325
1D-1.3%
1W+3.3%
1M+4.1%
3M-0.3%
6M+2.6%
YTD-0.5%
1Y+3.4%
ATR %1.9%
52w lowhigh6.5% off high

What Create SD does

Regional Japanese drugstore chain based in Shizuoka, selling OTC drugs, cosmetics and daily goods.

Products and services

  • Drugstore retail
  • Dispensing pharmacy services

Customers

  • Retail consumers in the Shizuoka/Kanto region

Where it sits in the supply chain

  • Consumer Staples
  • Retail pharmacy
  • Drugstore chain retail

What could go right

  • Regional store expansion

What could go wrong

  • Competition from larger national drugstore chains

Moat: narrow (distribution). Regional drugstore network scale, smaller than national chains like Sundrug/Ain.

Headquarters: Shizuoka, Japan · Founded: 1985 · Employees: 5,478

Named competitors

Create SD at a glance

Size Create SD (3148.T) is a Japan Consumer Staples company (Drugstore Chains) with a market value of $1.32B, the 624th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,325 on 18 Nov 2026.

Performance Over six months the shares gained 2.6%, against +2.6% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 18 in its peer set.

Growth Revenue grew 8.7% over the last twelve months (peer median +5.3%); the operating margin is 4.7% (peer median 4.8%).

Valuation It trades at 0.3× enterprise value to sales against a peer median of 0.8× (2nd cheapest of 18).

Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -19 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 8.3 points above its cost of capital (5.0% WACC).

Next results Next results expected around 12 Jan 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 20263148.T 104Peer median 104
Six months, rebased to 100: Create SD against the median of its 17 peers (local-currency closes).

Create SD financials

Reported figures in JPY; fiscal year ends 2026-05-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥505B¥497B¥457B¥422B¥381B
Revenue growth—+9%+8%+11%—
Gross profit¥122B¥121B¥114B¥105B¥98.8B
EBITDA¥30.4B¥30.5B¥28.3B¥25.2B¥23.3B
Net income¥16.8B¥17.0B¥15.7B¥13.7B¥12.9B
Free cash flown/a¥9.22B¥6.10B¥5.26B¥3.03B
Capital expendituren/a¥16.7B¥17.9B¥16.2B¥16.4B
Total debt¥1.05B¥1.41B¥0¥1.00M¥6.00M

Quarterly statements and history in the cockpit →

Create SD competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%9627002727603883MEDPLUS30140892673010179989GRDN2664303460359000278876496032336039390005043148.T6-month return →1-month return →
Up and to the right = strong over both horizons. Create SD is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×2×4×9627002727603883MEDPLUSGRDN26646035906039390005043148.TRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Create SD is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%9627002727603883MEDPLUS3014083010179989GRDN2664303460359000278876496032333148.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Create SD is the large dot.

Create SD competitors and peer comparison

Head to head with its named competitors (3148.T vs 7649.T vs 9989.T vs 9627.T)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Create SD 3148.T$1.32B+3%+9%5%0.3×-11.5%
Sugi 7649.T$3.46B-9%+9%5%0.5×-9.0%
Sundrug 9989.T$3.07B+10%+4%6%0.6×-7.3%
Ain 9627.T$1.25B+2%+42%4%0.5×-6.5%

How Create SD compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Create SD against its 17 peers (data as of 18 Nov 2026)
Measure3148.TPeer medianRank in peer set
1-month return+4.1%+1.1%6th highest of 18
6-month return+2.6%+2.6%9th highest of 18
Distance from 52-week high-6.5%-21.6%5th highest of 18
Revenue growth (TTM)+8.7%+5.3%7th highest of 18
Operating margin4.7%4.8%8th lowest of 18
EV / Sales0.3×0.8×2nd cheapest of 18
Growth the price implies (Req g, 7 yrs)-11.5%-7.3%3rd least demanding of 16
Growth delivered (Del g)+8.0%+12.4%6th lowest of 16
Hurdle (Req g minus delivered)-19.5 pp-19.9 pp8th most demanding of 16
ROIC minus cost of capital+8.3 pp+6.8 pp7th highest of 18
EV / EBITDA5.9×7.5×3rd cheapest of 8
Net debt / EBITDA-1.0×0.1×2nd least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Create SD 3148.TJapan$1.32B+3%+9%5%0.3×-11.5%+8.0%
Ain 9627.TJapan$1.25B+2%+42%4%0.5×-6.5%+16.9%
Yixintang Pharmaceutical 002727.SZChina$1.16B+4%-2%3%0.5×-16.0%+6.5%
LBX Pharmacy Chain Joint Stock 603883.SSChina$1.71B+13%+3%5%0.8×-10.7%+9.7%
MedPlus Health Services MEDPLUS.NSIndia$771M-36%+21%4%1.1×18.6%+17.6%
Anhui Huaren Health Pharmaceutical 301408.SZChina$745M-32%+15%8%1.1×-7.5%+23.3%
Genky DrugStores 9267.TJapan$728M+3%+8%5%0.6×n/an/a
Shu Yu Civilian Pharmacy 301017.SZChina$701M-11%+9%2%0.8×1.1%+17.4%
Sundrug 9989.TJapan$3.07B+10%+4%6%0.6×-7.3%+5.8%
Guardian Pharmacy Services GRDNUnited States$3.09B+30%+5%6%2.1×4.4%+16.8%
Cawachi 2664.TJapan$562M+31%-1%2%0.2×-6.1%0.0%
Qol 3034.TJapan$561M+26%+5%6%0.4×-16.6%+12.4%
Beijing Konruns Pharmaceutical 603590.SSChina$558M-33%-1%17%4.2×12.4%+2.7%
Luyan Pharma 002788.SZChina$514M-32%+3%3%0.4×-0.4%+6.5%
Sugi 7649.TJapan$3.46B-9%+9%5%0.5×-9.0%+10.9%
DaShenLin Pharmaceutical 603233.SSChina$3.64B+10%+7%8%1.1×-9.5%+13.6%
Yifeng Pharmacy Chain 603939.SSChina$4.84B+16%+5%10%1.3×-9.3%+13.2%
Landfar Bio-medicine 000504.SZChina$351M-22%+497%-2%3.1×n/an/a

Questions

Who are Create SD's main competitors?
Named competitors: Sugi Holdings (7649.T), Sundrug (9989.T), Ain Holdings (9627.T). The cockpit's measured peer set (industry) also includes Ain (9627.T), Yixintang Pharmaceutical (002727.SZ), LBX Pharmacy Chain Joint Stock (603883.SS), MedPlus Health Services (MEDPLUS.NS), Anhui Huaren Health Pharmaceutical (301408.SZ), Genky DrugStores (9267.T).
Is Create SD expensive compared with its peers?
On ev / sales it trades at 0.3× against a peer median of 0.8×, 2nd cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -19 pp: the price already allows for a slowdown.
How has Create SD stock performed?
Over six months to 18 Nov 2026 the shares returned +2.6% against +2.6% for the median peer; over one year +3.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.